Viking Therapeutics reports VK2735 weight maintenance data with less frequent dosing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. NDAQ
7. QGEN
8. CSX
9. LRCX
10. BFH

Go back to Viking Therapeutics reports VK2735 weight maintenance data with less frequent dosing

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

September 22, 2026 7:05 AM EDT

22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed

Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment

Up to 97% of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months

Up to 90% of Weight Loss Maintained Following Transition to Monthly Dosing for Three Months

Excellent Tolerability Observed During Maintenance Dosing with GI Adverse Event Rates Similar to Placebo

... More